Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04503252
Other study ID # 2019-02229; me20Osthoff2
Secondary ID
Status Completed
Phase
First received
Last updated
Start date January 14, 2020
Est. completion date March 28, 2022

Study information

Verified date March 2022
Source University Hospital, Basel, Switzerland
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

Given the paucity of pharmacological data on cefazolin treatment of Methicillin-susceptible S. aureus (MSSA) complicated S. aureus infection (CSAI), the primary purpose of this study is to investigate the probability of pharmacological target attainment (in the blood and infected tissue) with standard intermittent bolus administration of cefazolin in patients with CSAI caused by MSSA by determining plasma concentrations of cefazolin and exact Minimum inhibitory concentration (MICs) of the causative MSSA strains in patients with various disease severities (e.g. critically ill vs. noncritically ill patients). - Sub-study quantitative measurement of Torque Teno virus (TTV): The primary purpose of this sub-study is to describe the viral kinetics of TTV in CSAI patients and to explore the association of TTV viremia with clinical outcomes and molecular markers of activation of the immune system. - Sub-study investigating antibiotic concentrations in sweat as a non-invasive therapeutic drug monitoring


Recruitment information / eligibility

Status Completed
Enrollment 50
Est. completion date March 28, 2022
Est. primary completion date March 28, 2022
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - CSAI caused by MSSA. CSAI is defined as MSSA BSI with a positive follow-up blood culture result for MSSA or the presence of a site of infection remote from the primary focus caused by hematogenous seeding (e.g. endocarditis, vertebral osteomyelitis) or extension of the infection beyond the primary focus (e.g. septic thrombophlebitis or abscess); or deep-seated infections caused by MSSA (e.g. osteoarticular infections, deepseated abscesses). - Current or intended treatment with cefazolin Exclusion Criteria: - Previous enrolment into the current study within 30 days - Hemodialysis (patients on hemofiltration are eligible) - Patients who are very likely to stop treatment with cefazolin in the next 48 hours as per treating physician (because of treatment failure, switch to oral medication, palliative care, allergy etc.) or who are very likely to be discharged in the next 48 hours as per treating physician. - Outpatients - Women who are pregnant (special pharmacokinetic) - Polymicrobial infection except concomitant isolation of a likely contaminant (e.g. Staphylococcus epidermidis or Propionibacterium acnes) or an anaerobic pathogen. If an additional pathogen is identified after inclusion of the patient into the study, the patient will remain in the study. - Not-complicated S. aureus infections: non-bacteremic skin- and soft tissue or small Joint infections without deep-seated abscesses (as these patients will be quickly switched to oral antibiotics) - CSAI caused by methicillin-resistant S. aureus (MRSA) Additional exclusion criteria for the sub-study investigating cefazolin concentrations in sweat: - Allergic to pilocarpine - Continuous oxygen therapy without the possibility to interrupt oxygen administration for 10min - Pacemaker

Study Design


Intervention

Other:
Blood samples for the measurement of the concentration of cefazolin
Blood samples for the measurement of the concentration of cefazolin will be collected on the 1st (mid-dose and trough sample), 3rd (mid-dose and trough sample),7th and 14th day (for both only trough sample) of cefazolin treatment (+/-1-5 day) and if applicable in weekly intervals during outpatient parenteral antibiotic treatment (usually within 4 weeks after inclusion; only in patients on outpatient continuous parenteral antibiotic treatment).
S. aureus culture isolate
The S. aureus culture isolate will be subjected to exact cefazolin MIC determination and to measurement of the level of cefazolin tolerance.
structured telephone interview
Structured telephone interview for Patient follow- up after 30 days
Sub-study quantitative measurement of Torque Teno virus
An additional EDTA sample will be drawn for quantitative polymerase chain reaction (PCR) of TTV DNA and analyses of cytokines and other parameters of the activation state of the immune system.
Sub-study investigating cefazolin concentrations in sweat
For each visit of included patients, a sweat sample will be collected via a CE certified Macroduct Sweat Collector. Eccrine sweat glands of the lower forearms are stimulated by pilocarpine (a parasympathomimetic) as well as a local current for 5min. Sweat is subsequently collected by capillary containers during 30min and transferred to small tubes on dry ice. Sweat sample analysis is conducted using mass spectrometry.

Locations

Country Name City State
Switzerland University Hospital Basel, Division of Internal Medicine Basel

Sponsors (2)

Lead Sponsor Collaborator
University Hospital, Basel, Switzerland propatient foundation Basel

Country where clinical trial is conducted

Switzerland, 

Outcome

Type Measure Description Time frame Safety issue
Primary Trough concentration of cefazolin in plasma samples Trough concentration of cefazolin measured in plasma samples 1st (mid-dose and trough sample), 3rd (mid-dose and trough sample),7th and 14th day (for both only trough sample) of cefazolin treatment (+/-1-5 day) and if applicable in weekly intervals during outpatient parenteral antibiotic treatment (within 4 weeks)
Primary Total plasma concentrations of cefazolin in plasma samples Total plasma concentrations of cefazolin in plasma samples 1st (mid-dose and trough sample), 3rd (mid-dose and trough sample) of cefazolin treatment (+/-1-5 day) and if applicable in weekly intervals during outpatient parenteral antibiotic treatment (within 4 weeks)
Primary Free drug concentrations of cefazolin in plasma samples Free drug concentrations of cefazolin in plasma samples 1st (mid-dose and trough sample), 3rd (mid-dose and trough sample) of cefazolin treatment (+/-1-5 day) and if applicable in weekly intervals during outpatient parenteral antibiotic treatment (within 4 weeks)
Primary Trough concentration of cefazolin in sweat samples Trough concentration of cefazolin measured in sweat samples 1st, 3rd,7th and 14th day of cefazolin treatment (+/-1-5 day) and if applicable in weekly intervals during outpatient parenteral antibiotic treatment (within 4 weeks)
Primary Total sweat concentrations of cefazolin Total sweat concentrations of cefazolin 1st, 3rd,7th and 14th day of cefazolin treatment (+/-1-5 day) and if applicable in weekly intervals during outpatient parenteral antibiotic treatment (within 4 weeks)
Primary Free drug concentrations of cefazolin in sweat samples Free drug concentrations of cefazolin in sweat samples 1st, 3rd,7th and 14th day of cefazolin treatment (+/-1-5 day) and if applicable in weekly intervals during outpatient parenteral antibiotic treatment (within 4 weeks)
Primary Target attainment (100%fT>MIC) Antibiotic susceptibility of the isolated pathogens determined by the use of an Minimum inhibitory concentration (MIC) test strip. Target attainment (100%fT>MIC) will be calculated for each patient and for each day the patient was sampled. Target attainment is defined as a measured free trough plasma concentration of cefazolin above the measured exact MICs of the causative pathogens at all points of time sampled. 1st, 3rd,7th and 14th day of cefazolin treatment (+/-1-5 day) and if applicable in weekly intervals during outpatient parenteral antibiotic treatment (within 4 weeks)
Secondary Pharmacological target attainment (100%fT>MIC) in infected tissue For the analysis of pharmacological target attainment (100%fT>MIC) in infected tissue (only patients with a suggestive focus or metastatic complication of BSI will be included for this analysis) free trough concentration of cefazolin will be measured in plasma samples. 1st, 3rd,7th and 14th day of cefazolin treatment (+/-1-5 day) and if applicable in weekly intervals during outpatient parenteral antibiotic treatment (within 4 weeks)
Secondary Attainment of an accepted threshold for toxicity (100%fT>10xMIC) in blood For the analysis of attainment of an accepted threshold for toxicity (100%fT>10xMIC) in blood, trough free concentration of cefazolin will be measured in plasma samples. Attainment of the threshold for toxicity is defined as measured free trough plasma concentration of cefazolin above at least 10x the measured exact MIC or above the clinical breakpoint MIC of the causative pathogen as published by the European Committee on Antimicrobial Susceptibility Testing at one time point or more. Cefazolin concentrations in sweat will be compared between patients with attained toxicity and non-attained thresholds in plasma. 1st, 3rd,7th and 14th day of cefazolin treatment (+/-1-5 day) and if applicable in weekly intervals during outpatient parenteral antibiotic treatment (within 4 weeks)
Secondary Level of cefazolin tolerance of the isolated pathogen The level of cefazolin tolerance of the isolated pathogen will be determined by the tolerance disc test as well as through time-kill curves. The level of tolerance determines the required antibiotic concentration to achieve bactericidal killing. 1st, 3rd,7th and 14th day of cefazolin treatment (+/-1-5 day) and if applicable in weekly intervals during outpatient parenteral antibiotic treatment (within 4 weeks)
Secondary TTV substudy: quantification of DNA For the TTV substudy DNA will be extracted from ethylenediaminetetraacetic acid (EDTA) blood and quantified 1st, 3rd,7th and 14th day of cefazolin treatment (+/-1-5 day) and if applicable in weekly intervals during outpatient parenteral antibiotic treatment (within 4 weeks)
Secondary TTV substudy: quantification of cytokines Cytokines as a markers of the activation status of the immune system will be quantified by using commercially available ELISA kits. 1st, 3rd,7th and 14th day of cefazolin treatment (+/-1-5 day) and if applicable in weekly intervals during outpatient parenteral antibiotic treatment (within 4 weeks)
See also
  Status Clinical Trial Phase
Active, not recruiting NCT04210505 - Nasal Decolonization of Dialysis Patients Noses Phase 4
Not yet recruiting NCT05361135 - 18-fluorodeoxyglucose Positron Emission Tomography/Computed Tomography in S. Aureus Bacteraemia N/A
Completed NCT02804711 - A Clinical Trial to Evaluate a Recombinant Staphylococcus Aureus Vaccine (Escherichia Coli) in Healthy Adults Phase 1
Completed NCT02282605 - Study of the Nasal Decolonisation of Staphylococcus Aureus (SA) and the Safety and Tolerability of XF-73 Nasal Gel in Healthy Subjects Phase 1/Phase 2
Recruiting NCT06319235 - Clinical Trial to Demonstrate the Safety and Efficacy of DUOFAG® Phase 1/Phase 2
Enrolling by invitation NCT06317688 - Effectiveness of Highly Purified Anhydrous (HPA) Lanolin Versus Extra-Virgin Coconut Oil in Preventing Subacute Lactation Mastitis Phase 1
Withdrawn NCT02741869 - Photodisinfection for the Decolonization of Staphylococcus Aureus in Hemodialysis Patients N/A
Completed NCT03966040 - A Clinical Trial to Evaluate a Recombinant Staphylococcus Aureus Vaccine (Escherichia Coli) in Healthy Adults Phase 1
Completed NCT04803708 - Bacteriophage Therapy TP-102 in Diabetic Foot Ulcers Phase 1/Phase 2
Recruiting NCT05117398 - Dalbavancin Versus Standard Antibiotic Therapy for Catheter-related Bloodstream Infections Due to Staphylococcus Aureus Phase 3
Not yet recruiting NCT06456424 - Bacteriophage Therapy for Methicillin-Sensitive Staphylococcus Aureus Prosthetic Joint Infection Phase 1/Phase 2
Completed NCT02820883 - A Study of a Recombinant Staphylococcus Aureus Vaccine (Escherichia Coli) in Healthy Adults Phase 0
Active, not recruiting NCT01879761 - Immune Resolution After Staphylococcus Aureus Bacteremia
Completed NCT01375621 - Livestock Contact and MRSA in Rural Areas
Recruiting NCT00532324 - Community-Acquired Methicillin Resistant Staphylococcus Aureus Colonization in Pregnant Women and Infections in Newborns N/A
Recruiting NCT06368856 - Pharmacology of Mupirocin in Nasal Application in Healthy Volunteers: Monocentric Study Phase 1
Not yet recruiting NCT05899140 - Adjunctive Clindamycin for the Treatment of Skin and Soft Tissue Infections, a Randomized Controlled Trial Phase 4
Completed NCT01792804 - Staphylococcus Aureus Bacteremia Antibiotic Treatment Options Phase 3
Enrolling by invitation NCT04897971 - Serum Based Diagnosis of and Monitoring of Infection Recovery in Orthopedic Spine Implant Infections
Completed NCT00572910 - A Study to Evaluate the Safety and Immunogenicity of V710 in Adults With Kidney Disease on Hemodialysis (V710-005)(COMPLETED) Phase 2